

**REMARKS**

This application is a continuation-in-part of application Serial No. 08/765,337 and is identical to the disclosure of that application with the exception of a single sentence added to page 5 of the specification, first full paragraph. This statement indicates that the fusion protein of the present invention has no mouse IL-3 activity. This is an inherent property of the fusion protein and is illustrated in the examples at pages 50 and 51. Applicants retain their priority rights to both the underlying PCT and Japanese priority applications in accordance with *In re Davies et al* 177 USPQ 381 (CCPA 1973).

The claims now before the examiner are the same claims that were presented in the parent application with the amendment filed July 27, 2000. The title of this application has been amended and also passages at pages 11-13 of the specification adjusted.


With this filing there is a comprehensive Information Disclosure Statement bringing forward the art of record in the parent application.

It is submitted that claims 10-18 are in condition for allowance. Favorable action is solicited.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: \_\_\_\_\_

  
Arthur R. Crawford  
Reg. No. 25,327

ARC:pfc  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100